Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
27.05. | Vaccinex, Inc.: Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting | 1 | GlobeNewswire (USA) | ||
13.05. | AbTherx, Inc: AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets | 272 | ACCESS Newswire | AbTherx and Single Cell Technology incorporate ActivMAb® Technology into Atlas Mouse and AbTheneum antibody discovery platforms MOUNTAIN VIEW, CA / ACCESS Newswire / May 13, 2025 / AbTherx, Inc., a... ► Artikel lesen | |
21.04. | Vaccinex berichtet: Pepinemab verstärkt Immunantwort bei Krebserkrankungen | 3 | Investing.com Deutsch | ||
21.04. | Vaccinex reports pepinemab boosts immune response in cancer | 1 | Investing.com | ||
21.04. | Vaccinex, Inc.: Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR) | 1 | GlobeNewswire (USA) | ||
15.04. | VACCINEX, INC. - 10-K, Annual Report | 2 | SEC Filings | ||
01.04. | VACCINEX, INC. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 2 | SEC Filings | ||
VACCINEX Aktie jetzt für 0€ handeln | |||||
27.03. | VACCINEX, INC. - 15-12G, Securities registration termination | 2 | SEC Filings | ||
19.03. | VACCINEX, INC. - 8-K, Current Report | 1 | SEC Filings | ||
17.03. | VACCINEX, INC. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 2 | SEC Filings | ||
10.03. | Vaccinex plans Nasdaq exit as Alzheimer market pressure grows | 3 | Pharmaceutical Technology | ||
07.03. | Vaccinex plans to delist common stock from Nasdaq | 1 | Seeking Alpha | ||
07.03. | Vaccinex, Inc.: Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market | 189 | GlobeNewswire (Europe) | ROCHESTER, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTC: VCNX) ("Vaccinex" or the "Company"), a clinical-stage biotechnology company pioneering a differentiated approach to treating... ► Artikel lesen | |
07.03. | VACCINEX, INC. - 8-K, Current Report | - | SEC Filings | ||
17.12.24 | Vaccinex, Inc.: Vaccinex Announces Receipt of Delisting Notification from Nasdaq | 170 | GlobeNewswire (Europe) | ROCHESTER, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) ("Vaccinex" or the "Company"), a clinical-stage biotechnology company pioneering a differentiated approach to treating... ► Artikel lesen | |
18.11.24 | Vaccinex, Inc.: Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update | 212 | GlobeNewswire (Europe) | Actively Exploring Partnership for Alzheimer's DevelopmentSupplementary Financing Concluded in Q4 ROCHESTER, N.Y., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage... ► Artikel lesen | |
05.11.24 | Vaccinex, Inc.: Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting | 206 | GlobeNewswire (Europe) | ROCHESTER, N.Y., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative... ► Artikel lesen | |
14.08.24 | Vaccinex, Inc.: Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer's Disease and Plans to Pursue a Development Partnership | 186 | GlobeNewswire (Europe) | ROCHESTER, N.Y., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Vaccinex (Nasdaq: VCNX) today provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in Alzheimer's... ► Artikel lesen | |
31.07.24 | Vaccinex, Inc.: Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer's Disease | 246 | GlobeNewswire (Europe) | Results affirm expectation of a novel mechanism of action targeting astrocyte activation to delay progression of Alzheimer's disease from early stage Mild Cognitive Impairment Findings echo previous... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 91,15 | +0,55 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
EVOTEC | 7,164 | -0,44 % | Evotec-Aktie: Kurs legt zu (6,734 €) | Am deutschen Aktienmarkt notiert die Evotec-Aktie derzeit etwas fester. Zuletzt zahlten Investoren für das Wertpapier 6,73 Euro. Der Anteilsschein von Evotec verzeichnet gegenwärtig einen Preisanstieg... ► Artikel lesen | |
CUREVAC | 4,580 | -0,56 % | EQS-News: CureVac Announces Voting Results of General Meeting | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Hauptversammlung
CureVac Announces Voting Results of General Meeting
24.06.2025 / 22:09 CET/CEST
Für den Inhalt der... ► Artikel lesen | |
AMGEN | 240,45 | +0,82 % | ROUNDUP/Aktien New York Schluss: Gewinne - 'Iran-Angriff eine Gesichtswahrung' | NEW YORK (dpa-AFX) - Der Nahost-Krieg hat am Montag die Richtung an den US-Börsen bestimmt. Die wichtigsten US-Indizes legten am Ende kräftig zu und erreichten kurz vor dem Handelsschluss Tageshöchststände.... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,463 | -2,11 % | Defence Therapeutics Inc.: Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology | Montreal, Quebec--(Newsfile Corp. - June 9, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
NUREXONE BIOLOGIC | 0,450 | +1,35 % | Breaking News: Prestigeträchtige Auszeichnung für NurExone! | ||
IBIO | 0,703 | 0,00 % | Pharos iBio Receives IND Approval for PHI-501 Phase 1 Trial | ||
ARROWHEAD PHARMACEUTICALS | 13,400 | -2,37 % | Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results | PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting... ► Artikel lesen | |
COHERUS ONCOLOGY | 0,629 | +0,51 % | Coherus Oncology, Inc.: Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics | REDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc.... ► Artikel lesen | |
VOYAGER THERAPEUTICS | 2,526 | -0,63 % | Voyager Therapeutics, Inc.: Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication | LEXINGTON, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced... ► Artikel lesen | |
OPGEN | 2,600 | 0,00 % | OPGEN INC - 8-K, Current Report | ||
MEREO BIOPHARMA | 2,330 | -2,51 % | Mereo BioPharma Group plc: Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights | Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI) Cash of $62.5 million as of March 31, 2025, expected to fund operations into 2027 LONDON, May 13, 2025 (GLOBE... ► Artikel lesen | |
APELLIS PHARMACEUTICALS | 15,634 | -0,53 % | Swedish Orphan Biovitrum AB: Sobi and Apellis: Aspaveli/Empaveli Demonstrates Sustained One-Year Efficacy in Phase 3 Study for Rare Kidney Diseases | STOCKHOLM, June 6, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) and Apellis Pharmaceuticals, Inc. today presented new data from the open-label period of the Phase 3 VALIANT study, investigating... ► Artikel lesen | |
BENITEC BIOPHARMA | 12,350 | 0,00 % | Benitec Biopharma Inc.: Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update | -Fifth Subject in BB-301 Phase 1b/2a Clinical Treatment Study safely treated in February 2025- -Interim clinical study update to be presented in late-breaking oral presentation at the 2025 Muscular... ► Artikel lesen | |
CYBIN | 7,400 | +1,37 % | Neural Therapeutics: Innovative Meskalin-Therapien für psychische Gesundheit |